Secondary BRCA1 mutations able to restore the wild-type gene reading frame and DNA repair in ovarian carcinomas have been associated to resistance to cisplatin and PARP inhibitors 10, implying the need for new target discovery. This evidence concerns the gene BRCA1 and ovarian carcinoma.